

Israel's Joy Ventures rebrands as Corundum Neuroscience to spur neuroscience technology innovation

09 November 2023 | News

New fund launched to implement 'Lab-to-Life' model to support neuroscience research

Israel-headquartered Corundum Neuroscience, formerly Joy Ventures, has announced the launch of its new neuroscience-focused venture builder and fund to spur neuroscience research and innovation.

The newly rebranded Corundum Neuroscience works with researchers and entrepreneurs with commercially applicable ideas to build and grow companies developing innovative solutions spanning a range of health and disease areas, including anxiety, depression, post-traumatic stress disorder (PTSD), chronic pain, sleep and neurodegenerative disorders.

Corundum Neuroscience's lab-to-life model supports the entire innovation journey, from the earliest stages of research and concept, through commercialisation to facilitate the long-term success and impact of its portfolio companies. The decision to transition from Joy Ventures to Corundum Neuroscience signifies the company's sharpened focus on facilitating greater neuroscience research and innovation, with its mission to expand availability of solutions that improve people's daily lives across the globe.

Corundum Neuroscience's portfolio of companies includes digital self-neuromodulation therapies developer Gray Matters Health, leading provider of therapist-guided neuro-feedback for home use Myndlift, and personalised sleep optimisation developer NYX Technologies.